Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration Wills Eye Institute receives IRB approval to treat dry-AMD using ACT's hESC-derived retinal pigment epithelial (RPE) cells
Document Type
Popular Press
Publication Date
1-17-2012
Abstract
Press release announcing:
MARLBOROUGH, Mass., Jan 17, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the Phase 1/2 clinical trial for dry age-related macular degeneration (dry AMD) using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
Recommended Citation
Regillo, M.D., Carl, "Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration Wills Eye Institute receives IRB approval to treat dry-AMD using ACT's hESC-derived retinal pigment epithelial (RPE) cells" (2012). Wills Eye Hospital Papers. Paper 11.
https://jdc.jefferson.edu/willsfp/11
